Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vets warned of monensin toxicity in dogs
dog walking
So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.
SPC for Kexxtone changed after rise in accidental exposure reports
 
Veterinary surgeons are being warned of the risks of monensin exposure to non-target species.

In 2015, the Veterinary Medicines Directorate (VMD) saw an increase in reports of accidental canine exposure to Kexxtone 32.4g (monensin), the drug used in cattle feed to control ketosis.

Reported symptoms included neurological issues, such as seizures, lethargy, muscular problems, locked jaws, problems with balance, confusion, vomiting and death.

So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.

As a result, the VMD requested that the following warning be added to the Summary of Product Characteristics (SPC):

'Do not allow dogs, horses, other equines or guinea fowl access to formulations containing monensin. Due to the risk of bolus regurgitation, do not allow these species access to areas where treated cattle have been kept. Ingestion or oral exposure to monensin can be fatal in these species.'

Writing in Veterinary Record letters, the VMD suggested that when prescribing Kexxtone, vets should advise clients of the dangers to non-target species, whilst also remaining aware of the effects of monensin when dealing with cases that present neurological or myopathic problems.

Vets are encouraged to report all adverse reactions to the applicable marketing authorisation holder, or to the VMD via: www.gov.uk/report-veterinary-medicine-problem

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.